Search
Resources
Gain key insights quickly: engage with disease and treatment resources.
Interactive Posters
Rifaximin Plus Lactulose Is More Efficacious Than Lactulose Alone for the Prevention of Overt Hepatic Encephalopathy in Patients With or Without Ascites
Kris V. Kowdley, MD, et al.
Narrated by: Kris Kowdley, MD
Graphic Abstracts
Rifaximin for the Reduction of Risk of Overt HE Recurrence
Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
Videos
Impact of Rifaximin Use Following an Initial Overt Hepatic Encephalopathy Hospitalization on Rehospitalization and Costs
Jesudian AB, et al. J Med Econ. 2023;26(1): 1169-1177.
Interactive Posters
Association Between Symptoms in Irritable Bowel Syndrome With Diarrhea: A Pooled Correlation and Tricomposite Endpoint Analysis of Two Phase 3, Randomized, Placebo-Controlled, Rifaximin Trials
Kyle Staller, MD, MPH, et al.
Narrated by: Kyle Staller, MD, MPH
Graphic Abstracts
Two-Week Course of Rifaximin for Patients with IBS-D
Pimentel M, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32.
Two-Week Repeat Rifaximin Course in Initial IBS-D Responders
Lembo A, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113-1121.
Videos
Efficacy of Rifaximin on Bloating in Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): A Pooled Analysis of Three Phase 3 Randomized, Placebo-Controlled Trials
Lacy BE. United European Gastroenterology (UEG) Week 2020, October 11-13, 2020, Virtual.
Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points
Lacy BE, et al. Clin Ther. 2023;45(3):198-209.
Trusted External Resources for Healthcare Providers to Share With Patients and Their Caregivers
Advanced Liver Disease
IBS-D
IBS-D
Overt HE
Diseases of Gut Brain Interactions
AASLD = American Association for the Study of Liver Diseases; AGA = American Gastroenterological Association; HE = hepatic encephalopathy; IBS = irritable bowel syndrome; IFFGD = International Foundation for Gastrointestinal Disorders; NIDDK = National Institute of Diabetes and Digestive and Kidney Diseases; NIH = National Institutes of Health.
Search
*Required field.
Select a product*
Select a therapeutic area*
Enter keyword(s)